Erratum: Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields (Neuro-Oncology Advances (2022) 4:1 (vdac096) DOI: 10.1093/noajnl/vdac096)

Manjari Pandey, Joanne Xiu, Sandeep Mittal, Jia Zeng, Michelle Saul, Santosh Kesari, Amir Azadi, Herbert Newton, Karina Deniz, Katherine Ladner, Ashley Sumrall, W. Michael Korn, Emil Lou

Research output: Contribution to journalComment/debatepeer-review

Abstract

This is a corrigendum to: Manjari Pandey, Joanne Xiu, Sandeep Mittal, Jia Zeng, Michelle Saul, Santosh Kesari, Amir Azadi, Herbert Newton, Karina Deniz, Katherine Ladner, Ashley Sumrall, W Michael Korn, Emil Lou, Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac096, https:// doi.org/10.1093/noajnl/vdac096. In the originally published version of this manuscript, PIK3CA MT vs WT, NF1 MT vs WT, and EGFR WT vs MT were incorrectly labeled in Figure 3. PFS values for PIK3CA MT and WT were incorrectly labeled in Supplementary Table 1. These errors have been corrected.

Original languageEnglish (US)
Article numbervdac164
JournalNeuro-Oncology Advances
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2022

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Erratum: Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields (Neuro-Oncology Advances (2022) 4:1 (vdac096) DOI: 10.1093/noajnl/vdac096)'. Together they form a unique fingerprint.

Cite this